Generic Drugs

  • Read more: Big relief for Big Pharma: Indian Patent Office rejects application for compulsory license
    Article

    Big relief for Big Pharma: Indian Patent Office rejects application for compulsory license

    By Aditya Gupta By a detailed order passed last week, the Indian Patent Office rejected an application for compulsory license filed by a generic drug manufacturer BDR Pharmaceuticals International Pvt. Ltd. (“BDR”) seeking a license of Bristol Myers Squibb’s (“BMS”) Indian patent for an anti-cancer drug. The Indian Patent Office found that BDR had not made out…

  • Read more: On Access and Accountability: Two Supreme Court Rulings on Generic Drugs
    Article

    On Access and Accountability: Two Supreme Court Rulings on Generic Drugs

    By Marcia Boumil and Gregory Curfman In 2013 the U.S. Supreme Court issued two important rulings in cases involving the marketing of generic drugs. In Federal Trade Commission v. Actavis, the Court addressed the law governing a controversial pharmaceutical marketing practice known as reverse payment agreements, or pay for delay – a byproduct of the Hatch-Waxman…